Halozyme Stock Falls On Unusually High Volume (HALO)

NEW YORK (TheStreet) -- Halozyme Therapeutics (Nasdaq:HALO) is trading at unusually high volume Friday with 2.7 million shares changing hands. It is currently at 4.2 times its average daily volume and trading down 23 cents (-2.1%) at $10.88 as of 11:29 a.m. ET.

Halozyme has a market cap of $1.06 billion and is part of the health care sector and drugs industry. Shares are up 18.6% year to date as of the close of trading on Thursday.

Halozyme Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of recombinant human enzymes that transiently modify tissue under the skin to facilitate injection of other therapies or correct diseased tissue structures for clinical benefits.

TheStreet Ratings rates Halozyme as a sell. The company's weaknesses can be seen in multiple areas, such as its weak operating cash flow and poor profit margins. You can view the full Halozyme Ratings Report.

See all heavy volume stocks in our stocks moving on unusual volume list or get investment ideas from our investment research center.

Interested in other stocks that are falling on unusually high volume? Get free SMS text alerts sent to you when the action happens by texting HVDOWN to 95370 or select from multiple alert options.

For more information on Halozyme Therapeutics Inc. click any of the following:

• Halozyme Therapeutics Inc. Stock Price

• Halozyme Therapeutics Inc. Analyst Ratings

• Halozyme Therapeutics Inc. Key Stats & Profile

• Halozyme Therapeutics Inc. Earnings

• Halozyme Therapeutics Inc. Ratio Comparison

• Halozyme Therapeutics Inc. Growth Rates

• Halozyme Therapeutics Inc. Balance Sheet

• Halozyme Therapeutics Inc. Cash Flow

• Halozyme Therapeutics Inc. Income Statement